Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
47,559,740
-
Total 13F shares
-
2,628,252
-
Share change
-
-543,484
-
Total reported value
-
$10,098,558
-
Price per share
-
$3.80
-
Number of holders
-
25
-
Value change
-
-$1,284,579
-
Number of buys
-
8
-
Number of sells
-
11
Institutional Holders of SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (SABS) as of Q4 2024
As of 31 Dec 2024,
SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (SABS) was held by
25 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,628,252 shares.
The largest 10 holders included
BVF INC/IL, MARSHALL WACE, LLP, Sessa Capital IM, L.P., VANGUARD GROUP INC, HB Wealth Management, LLC, GEODE CAPITAL MANAGEMENT, LLC, Pathstone Holdings, LLC, DIADEMA PARTNERS LP, MILLENNIUM MANAGEMENT LLC, and BlackRock, Inc..
This page lists
26
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.